

Amendments to the Claims

1. **(Currently amended)** A glycyrrhizin oral preparation in a form of a capsule for transmucosal absorption which comprises glycyrrhizin and an ester mixture of a C₆₋₁₈ fatty acid glycerol ester with a C₆₋₁₈ fatty acid macrogol ester in a weight ratio of the glycyrrhizin to the ester mixture being 1:0.05 to 1:10, wherein the capsule is made of a high-molecular polymer which is not degraded or dissolved in a digestive tract, or which is made of gelatin lined with said polymer, and wherein the capsule is collapsed by internal pressure in a large intestine to release the glycyrrhizin.

2. **(Original)** The glycyrrhizin preparation for transmucosal absorption according to claim 1, wherein the C₆₋₁₈ fatty acid is a saturated fatty acid.

3. **(Previously presented)** The glycyrrhizin preparation for transmucosal absorption according to claim 1, wherein the average molecular weight of the macrogol is 100 to 800.

4. **(Cancelled)**

5. **(Currently amended)** The glycyrrhizin preparation for transmucosal absorption according to claim 1, wherein the ratio by weight of the C₆₋₁₈ fatty acid glycerol ester to the C₆₋₁₈ fatty acid macrogol ester is ~~1:0.1-10~~ 1:0.1 to 1:10.

6. **(Previously presented)** The glycyrrhizin preparation for transmucosal absorption according to claim 1, which further comprises an organic acid, a chelating agent or a surfactant.

7. (Cancelled)

8. (Cancelled)